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Breathlessness is a common and distressing symptom 
for patients and carers, occurring in 50-90% of individuals 
in both malignant and non-malignant conditions.1 
In palliative care, the intensity of breathlessness 
frequently worsens as death is imminent.2 In spite of 
the prevalence of this symptom, patho-physiological 
processes remain poorly understood and the sensation 
is highly subjective, challenging development of 
evidence-based approaches.3 Available data suggest 
that there is more than one mechanism involved in the 
pathogenesis and manifestation of breathlessness.4 
An important consideration for health professionals is 
that in the real world of clinical practice, it is rare for 
an individual to have a single condition responsible 
for inducing the sensation of breathlessness. 
Breathlessness may be related to a prior condition, 
disease progression or it may be iatrogenic. In addition 
to causes of refractory breathlessness, commonly 
chronic obstructive pulmonary disease (COPD) and 
chronic heart failure (CHF) are comorbid conditions of 
individuals with cancer.5-7 Furthermore, breathlessness 
can also be associated with deconditioning associated 
with advanced illness.8,9 This means that the diagnosis, 
management and treatment of dyspnoea is complex 
and multifaceted and requires an appreciation of 
the biological, psychological and social impacts of 
breathlessness. Importantly, this requires appraisal of 
the individual’s needs and establishing the goals of 
therapy.10
Much of the data derived for recommendations relating 
to management of refractory breathlessness in cancer 
is derived from non-malignant populations.11 However, 
when disease is advanced and there is a need to 
focus on symptom management, these data provide 
an important foundation for empirical treatment. The 
heterogeneity of both patient populations and the 
symptom challenge evidence-based guidelines. In 
spite of these challenges, it is important that the 
clinician takes a systematic approach to the diagnosis 
and management of this symptom.
Assessment and planning: foundation of 
effective treatment
In order to develop an effective treatment plan it is 
important to identify the cause, where possible, and 
identify reversible causes such as pleural effusions, 
heart failure exacerbations or anaemia. Implementing 
strategies for monitoring the severity of breathlessness 
across the illness trajectory can assist in monitoring and 
managing exacerbations.1 Implementing a valid and 
reliable strategy for assessing breathlessness, such 
as a Visual Analogue Scale, Numerical Rating Scale 
or modified Borg Scale, can assist in monitoring and 
evaluating symptomatic treatment.12,13 Although there 
can be challenges in administering these instruments, 
implementing a measure routinely in clinical practice 
can assist in treatment and management. Although 
self-report is optimal, objective assessment using 
tools such as the Respiratory Distress Observation 
Scale may be useful.14 Calls for consensus of the 
choice of instruments for dyspnoea trials is an 
important consideration, particularly in the palliative 
care population.15 
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Abstract
Breathlessness is a common and distressing symptom in both malignant and non-malignant conditions. Both 
pharmacological and non-pharmacological strategies are necessary to minimise symptom burden and distress. 
Assessing the individual’s needs and clarifying the goals of treatment is an important first step in determining an 
effective treatment plan. Although the evidence supporting the use of some of these therapies is variable, there is 
an increasing evidence base to inform clinical decision making and treatment plans. Pharmacotherapy with opioids 
is a common and effective strategy for managing breathlessness, yet requires judicious titration and management. 
The adverse effects of opioid therapy, including constipation and drowsiness, can be anticipated and managed with 
adjunctive therapies. The use of oxygen in people who are hypoxaemic is supported, but is of limited value in people 
who are not hypoxaemic. Individualised strategies and advance care planning is important to avoid unnecessary 
hospitalisations and futile treatments at the end of life. There is a clear mismatch between the prevalence and burden 
of this problem and data to inform evidence-based guidelines. Refractory breathlessness is a fertile area for ongoing 
research and requires increased attention to address the burden of this highly prevalent symptom.
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Unfortunately, once breathlessness is refractory, many 
non-pharmacological interventions have been trialled 
and reversible causes assessed. As both malignant and 
non-malignant diseases progress, pharmacotherapy 
is an essential part of treatment integrated within a 
supportive care plan, recognising the physical, social, 
psychological and spiritual needs of patients and their 
families. As breathlessness is a common cause for 
hospitalisation, pre-empting hospital presentations 
with action plans in the event of sudden worsening of 
breathlessness is contingent upon effective palliative 
strategies. Evidence-based recommendations 
are limited by the current data available to inform 
decisions, underscoring the importance of ongoing 
research. Although there is increasing and emerging 
data in managing breathlessness,16 we are still limited 
by the absence of adequately powered clinical trials 
to definitively define treatment for many of the options 
currently used.1,17
Opioids
Although the mechanisms of action remain unclear, 
opioids are a frequently used and effective strategy 
for managing refractory breathlessness.17,18 Apart from 
morphine, which can be administered in immediate or 
sustained release oral preparations, subcutaneously 
or intravenously, other preparations include 
dihydrocodeine, hydromorphone and fentanyl. Opioids 
cause vasodilation and decrease the chemoreceptor 
response to hypercapnia and hypoxia. These responses 
may decrease the sensation of breathlessness through 
reducing preload and pulmonary congestion. The 
effect of opioids through decreasing anxiety and the 
subjective sensation of breathlessness, contributes 
to decreasing the respiratory rate and oxygen 
consumption.
Encouraging results have been found in the use 
of opioids in both malignant and non-malignant 
populations for relieving dyspnoea.17,19,20 Stigma and 
scepticism regarding opioids are important factors 
in the low uptake of opioid therapy.21 The commonly 
cited reasons for avoiding opioids, such as causing 
respiratory depression and reducing life expectancy, 
are not substantiated by available data when used 
chronologically in low doses. Minimising physical 
and psychological distress is not associated with 
shortening life expectancy. The optimal type, dose 
and mode of administration remain less clear and 
are the focus of ongoing research. Growing clinical 
experience indicates that judicious titration of 
dosage and anticipation of adverse effects, such 
as constipation, improves compliance with opiates. 
Adverse effects of opioids such as sleepiness or 
nausea are infrequent, and can be overcome by 
dose titration. Each patient should be assessed 
individually and appropriate dose adjustments made 
based on the patient's current medical condition. 
Starting with a low dose and up titrating slowly 
can allow the monitoring of adverse events and the 
tailoring of dosage. Constipation does not readily 
respond to dose titration and requires proactive 
bowel management and adjunctive administration of 
regular laxatives. For clinicians less experienced in 
opioid therapy prescription and management, enlisting 
the support of a more experienced colleague for 
mentorship and a pharmacist to assist with dosing is 
an important consideration.22 Although conceptually 
alluring, the use of nebulised opioids in the treatment 
of dyspnoea is not supported by individual studies nor 
a meta analysis.18 
Diverse pharmacological agents
Corticosteroids can be effective in the treatment of 
dyspnoea related to carcinomatous lymphangitis, 
superior vena cava syndrome, tracheal obstruction and 
bronchospasm associated with COPD and asthma.23 
Bronchodilators are used in the management of 
bronchospasm and may provide relief of breathlessness 
caused by airflow obstruction through relaxing the 
muscles around airways and increasing muscle tone.20 
Common bronchodilators include the short acting 
agents albuterol sulfate, levalbuterol and pirbuterol 
acetate, and the long-acting agents ipratropium 
bromide, salmeterol xinafoate, formoterol, tiotropium 
and terbutaline sulfate. Metered dose inhalers should 
be used with a spacer to improve the patient's ability to 
receive the full dose. Proper dosing is often dependent 
on perfecting the technique of these technically 
challenging devices. Failure to achieve therapeutic 
doses due to poor usage of the delivery system is not 
uncommon. Considering administration by a nebuliser 
may be a more reliable alternative, particularly if the 
patient is highly symptomatic.
Diuretics may be useful in the treatment of 
breathlessness caused by oedema. Generally 
loop diuretics, such as frusemide, are prescribed. 
Standard dosing for frusemide is 20-40mg orally, 
subcutaneously or intravenously once or twice a 
day. In individuals where heart failure is advanced 
or diuretics have been administered over a long 
period of time, diuretic resistance may be a problem 
requiring tailoring of the timing of dosage and the 
addition of a thiazide diuretic.24 Diuretics must be used 
cautiously given the potential for hypovolemia and 
electrolyte disturbances, particularly hypokalaemia. 
Consideration of electrolyte substitution, particularly 
potassium and magnesium should be considered.24 
Importantly, if the patient is incontinent, strategies to 
maintain patient comfort, dignity and preserve skin 
function should be implemented.
A recent meta-analysis conducted by Simon and 
colleagues did not show a beneficial effect of 
benzodiazepines for the relief of breathlessness in 
patients with advanced cancer and chronic obstructive 
pulmonary disease. These authors concluded that there 
was a small, non-significant trend towards a beneficial 
effect. Benzodiazepines caused more drowsiness 
compared to placebo, but less compared to morphine. 
They recommend considering benzodiazepines when 
opioids and non-pharmacological measures have 
failed to control breathlessness.25 The decision to 
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prescribe these agents should be based on the 
presence of anxiety impacting on the sensation 
of breathlessness.10 Benzodiazepines reduce the 
sensation of breathlessness through decreasing 
the anxiety associated with breathlessness. As 
benzodiazepines are metabolised in the liver to 
long-acting metabolites, short-acting drugs such as 
lorazepam are preferred, especially in the elderly or in 
patients with impaired liver function. Midazolam, when 
administered either subcutaneously or intravenously 
as an addition to an opioid, has been shown to 
reduce the terminal agitation and anxiety that may be 
associated with dyspnoea. 
There is some data to suggest that phenothiazines 
can be beneficial in the treatment of breathlessness.26 
In addition to reducing anxiety, phenothiazines 
possess anticholinergic properties that can be 
useful in managing increased respiratory secretions 
or in controlling nausea. Chlorpromazine has been 
found to be effective for the relief of dyspnoea in 
advanced cancer patients and also relieves terminal 
restlessness.27 Side-effects of phenothiazines may 
include hypotension and extrapyramidal effects, which 
may limit tolerability of these agents.  
Agents such as aminophylline and theophylline 
have been found to dilate the bronchi and improve 
diaphragmatic contractility in individuals with COPD, 
irrespective of any bronchoconstriction. There have 
also been reports of use in the palliative care setting.28 
Theophylline can also be useful in managing dyspnoea 
when combined with albuterol and ipratropium. 
Adverse effects include vomiting, hypokalaemia, 
hyperglycemia, tachycardia, cardiac dysrhythmias, 
neuromuscular irritability and seizures. Given the 
narrow therapeutic index, frequency of side-effects 
and the lack of evidence for efficacy, these agents 
are often not well tolerated in patients with advanced 
illness and their use should be reserved for people 
already established on these therapies.
Nebulised frusemide has been identified as a novel 
approach to dyspnoea management. The precise 
mode of action is unclear and it is thought to have 
multiple pathways of action. Potential modes of 
action are on the pulmonary stretch receptors and 
vasculature. A recent review has shown that this agent 
had a positive influence on dyspnoea and physiological 
measurements. However, the authors provide the 
caveat that findings are mixed and data to date comes 
from small trials and observational studies.29 Further 
investigation into the mechanistic and therapeutic 
actions of nebulised frusemide is warranted.
Oxygen therapy
Oxygen therapy continues to be very controversial 
in the management of dyspnoea, as there is little 
data supporting its use in the nonhypoxic patient,30 
although the role in people who transiently desaturate, 
particularly on exertion or overnight, can be made 
more easily. In patients who are hypoxic on room 
air, the benefit of supplemental oxygen is most 
likely related to flow of gas over the face. Currently, 
guidelines only recommend oxygen for dyspnoeic 
patients, with hypoxaemia of less than PaO2 of 
55-60mm Hg. A recently published systematic 
review of short-term oxygen in people with cancer 
who did not qualify for domiciliary oxygen, showed 
no symptomatic benefit.31 A recent international, 
multicentre, randomised comparator control study 
assessed long-term oxygen (≥15 hours/day) therapy 
versus air in a palliative care population, who had 
intractable dyspnoea at rest and on minimal exertion 
and did not qualify for home oxygen (NHMRC 375127/
NIH R01 AG026469-01). It showed that both oxygen 
and air delivered symptomatic benefit when used at 
two litres per minute via nasal prongs for more than 
15 hours a day.32
Non-pharmacological therapies 
Both invasive and non-invasive ventilation can 
be considered for progressive illnesses when the 
symptom is refractory to other therapies.33 However, 
the purpose and goals of treatment need to be 
carefully considered.34 There is an increasing concern 
of the futility of some decisions to provide mechanical 
ventilation.35 Escalation of symptom burden avoiding 
such scenarios can be achieved by careful planning 
and the institution of an action plan,36 providing 
strategies for self-management and instructions to 
health professionals where there is a deterioration in 
status about the person’s wishes. In life limiting illness, 
advance care planning is important to document the 
patient’s wishes and outline a clear plan for care.37 
There is a wide array of non-pharmacological 
therapies to manage dyspnoea, by either changing 
physiologic factors or modifying the subsequent 
emotional response associated with the sensation 
of breathlessness, as shown in table 1. Current 
research has been geared primarily toward patients 
with COPD, however the utility of this modality for both 
malignant and non-malignant disease is increasingly 
evident. Increasingly in cancer, there is an interest 
in rehabilitation programs similar to those seen in 
cardiac and respiratory rehabilitation.38,39 The aims of 
structured rehabilitation programs are to facilitate the 
coordination of care, provide information and facilitate 
access to resources, optimise physical and social 
function and provide psychosocial and peer support. 
The purpose of rehabilitation for patients with cancer 
is similar to that for patients with other diseases. 
The anticipated progression of disease, and any 
associated treatments must be considered carefully 
when goals are formed. When tumour progression 
and treatment causes a functional decline, or 
when the disease causes a fluctuation in abilities, 
rehabilitation assumes a supportive role of seeking 
to minimise the rate of decline, and goals should 
be adjusted to meet the needs of the patient and 
their families. The strong evidence for appropriate 
exercise in decreasing the symptom burden of 
dyspnoea and the increased adherence obtained 
from group settings is an important consideration.40,41 
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Table 1: Nonpharmacologic therapies for dyspnoea 
■ Reassurance and strategies to minimise the 
anxiety/dyspnoea cycle.
■ General supportive measures such as optimising 
nutritional status.
■ Positioning to support ventilation – sitting up or 
leaning forward.
■ Muscle strengthening through exercise and 
respiratory muscle training. 
■ Energy conservation techniques to minimise 
exertion and optimise activities of daily living.
■ Relaxation through techniques such as guided 
imagery and progressive muscle relaxation.
■ Breathing training through pursed lips and 
diaphragmatic breathing.
■ Counselling techniques such as mindfulness 
therapy.
■ Cool air and moving air across the face through 
use of a fan or gas administration via nasal 
cannula or mask.
■ Non-invasive ventilation. 
■ Acupuncture/acupressure.
■ Massage to promote relaxation and posture. 
The use of complementary and alternative treatments, 
such as massage, to decrease anxiety is increasing. 
Emotional responses to illness, such as anxiety and 
anger, can precipitate and worsen breathlessness.42 
Although some studies have assessed these 
therapies, the widespread recommendation is limited 
due to methodological factors such as small sample 
sizes.13 Relaxation and biofeedback techniques have 
demonstrated some efficacy in breathlessness in 
COPD and in patients with CHF. A critical strategy is 
addressing anxiety before it escalates into a situation of 
panic.43 Distraction is a useful technique and the playing 
of music and getting the patient to watch a movie 
can be useful. Breathing exercises and meditation 
strategies such as Buteyko and Pranyama, that use 
diaphragmatic breathing, can relieve the sensation of 
dyspnoea and promote a sense of control, however 
require a motivated and cognitively intact person.44,45 
Bernardi and colleagues demonstrated in a small 
study that training using the Ave Maria (in Latin), or a 
yoga mantra, improved psychological responses and 
increased baroreflex sensitivity.46 For these strategies to 
be effective, it is important to introduce these early in the 
illness, as when patients become highly symptomatic or 
drowsy, it is difficult to teach these techniques.
Some studies have suggested there is a benefit from 
acupuncture.47,48 Strategies that promote a sense 
of control are likely to improve the patient’s sense 
of wellbeing and minimise feelings of hopelessness. 
A recent trial of mindfulness therapy has shown 
benefits in relieving dyspnoea.49 It is important that 
patients and their families feel comfortable discussing 
alternative approaches and disclosing treatments they 
are undertaking.50 The potential for deleterious drug 
interactions with herbs and vitamins increases as 
metabolic derangements occur in the advanced stages 
of disease at the end of life. 
An important strategy in managing refractory 
breathlessness and maximising quality of life are energy 
conservation techniques.51 As symptoms worsen, 
activities of daily living become increasingly difficult. 
Implementing strategies and devices, such as walkers, 
to reduce energy expenditure can be useful.52 Involving 
allied health professionals, particularly occupational 
therapists, can contribute effectively to the dyspnoea 
management plan.
Palliative care
When increasing disability is evident and advanced 
disease processes are present, interventions and goals 
that focus on minimising or eliminating complications 
and providing comfort and support are important. 
Psychological and social support for the patient and 
family members are integral. Although a palliative 
approach can be provided by a range of health care 
professionals, particularly general practitioners, when 
breathlessness is refractory and front line treatments 
have been trialled unsuccessfully, specialist palliative 
care services should be accessed. It is not uncommon 
for existential distress to exacerbate symptoms, 
particularly dyspnoea.
Conclusion
Dyspnoea is a difficult and challenging symptom to 
manage for patients, their families and clinicians. 
Management of refractory breathlessness in patients 
with advanced disease remains challenging and 
further research is required to develop evidence-based 
strategies. Although there is a growing evidence base 
for interventions to manage dyspnoea, issues in clinical 
trial design challenge translation to evidence-based 
guidelines. Adequately powered, well controlled clinical 
trials are urgently needed to address the burden of 
this distressing symptom. A salient consideration in 
contemplating evidence-based interventions is that 
dyspnoea is a highly individualised and subjective 
symptom. As a consequence, the optimal treatment of 
dyspnoea will involve appraisal of the pathophysiological 
basis of the symptom, weighing of the potential risks and 
benefits of treatment and overall prognosis. Implicitly, this 
will entail an understanding of psychosocial, spiritual, 
and existential needs of the patient and their family.
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